Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study-Reference-Cited by-同舟云学术

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

Published:2016-09-19 Issue:2 Volume:52 Page:216-221
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Van Den Neste E,Schmitz N,Mounier N,Gill D,Linch D,Trneny M,Bouadballah R,Radford J,Bargetzi M,Ribrag V,Dührsen U,Ma D,Briere J,Thieblemont C,Bachy E,Moskowitz C H,Glass B,Gisselbrecht C

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2016213.pdf

Reference24 articles.

1. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184–4190.

2. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462–4469.

3. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2015; 51: 51–57.

4. Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013; 88: 890–894.

5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CARs moving forward: The development of CAR T-cell therapy in the earlier treatment course of hematologic malignancies;Seminars in Hematology;2024-08

2. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma;Medicine in Novel Technology and Devices;2024-06

3. Mechanisms of Cardiovascular Toxicities Induced by Cancer Therapies and Promising Biomarkers for Their Prediction: A Scoping Review;Heart, Lung and Circulation;2024-05

4. Clinical Efficacy and Mechanism of Action of Recently FDA Approved Anticancer Drugs: An Updated Review;Current Cancer Therapy Reviews;2024-04-09

5. Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive lymphoma, as a second-line treatment;Leukemia & Lymphoma;2023-11-15